Feb 10, 2026 | Uncategorized
J Addict Med. 2026 Feb 11. doi: 10.1097/ADM.0000000000001662. Online ahead of print.ABSTRACTOBJECTIVE: Determine whether employer-mandated transitions from low- to high-deductible health plans (HDHPs) are associated with delays in opioid use disorder (OUD)-related...
Feb 8, 2026 | Uncategorized
J Addict Med. 2026 Jan-Feb 01;20(1):126-129. doi: 10.1097/ADM.0000000000001506. Epub 2025 May 14.ABSTRACTBACKGROUND: Drug use-related stigma amplifies the harms faced by people who use drugs (PWUD). Media often dehumanizes PWUD, particularly those using xylazine, a...
Feb 5, 2026 | Uncategorized
Subst Use Addctn J. 2026 Feb 6:29767342251414537. doi: 10.1177/29767342251414537. Online ahead of print.ABSTRACTIndividuals with opioid misuse (OM) or opioid use disorder (OUD) frequently have co-occurring chronic pain (CP). Services for these chronic conditions are...
Feb 5, 2026 | Uncategorized
Res Sq [Preprint]. 2026 Jan 25:rs.3.rs-6059606. doi: 10.21203/rs.3.rs-6059606/v1.ABSTRACTBackground: The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between current...
Feb 5, 2026 | Uncategorized
Res Sq [Preprint]. 2026 Jan 13:rs.3.rs-7199750. doi: 10.21203/rs.3.rs-7199750/v1.ABSTRACTBACKGROUND: As xylazine-adulterated opioids become more prevalent in the U.S., people who use drugs (PWUD) face growing risks from sedation, withdrawal, and wounds. This study...
Feb 1, 2026 | Uncategorized
J Subst Use Addict Treat. 2026 Jan 31:209910. doi: 10.1016/j.josat.2026.209910. Online ahead of print.ABSTRACTINTRODUCTION: Office-based opioid treatment with buprenorphine for opioid use disorder (OBOT-BUP) is most effective when patients are retained in treatment...
